The profile and prognosis of patients hospitalised with heartf failure: The value of discharge blood pressure and cholesterol

International Heart Journal

Volumn 49, Issue 6, 2008, Pages 691-705

  Jindrich, Spinar ^a   Ondrej, Ludka ^a   Viktor, Musil ^a   Zbynek, Pozdisek ^a   Tomas, Pavlik ^b   Ladislav, Dusek ^b   Jiri, Vitovec ^c   Lenka, Spinarova ^c   Miroslav, Soucek ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b MASARYK UNIVERSITY   (Czech Republic)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Blood pressure; Cholesterol; Heart failure; Prognosis

Indexed keywords

CHOLESTEROL; CREATININE; HEMOGLOBIN; UREA; URIC ACID;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; SYSTOLIC BLOOD PRESSURE; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL; AGE; BLOOD; BLOOD PRESSURE; CHRONIC DISEASE; HEART MUSCLE ISCHEMIA; HEART STROKE VOLUME; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

AGE FACTORS; AGED; BLOOD PRESSURE; CHOLESTEROL; CHRONIC DISEASE; CREATININE; FEMALE; HEART FAILURE; HEART RATE; HEMOGLOBINS; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PATIENT DISCHARGE; PROGNOSIS; PROSPECTIVE STUDIES; STROKE VOLUME; UREA; URIC ACID;

EID: 60249096293     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.691     Document Type: Article

References (43)

1. Cleland JG, Swedberg K, Cohen-Solal A, et al. The Euro Heart Failure Survey of the EUROHEART survey programme. A survey on the quality of care among patients with heart failure in Europe. The Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The Medicines Evaluation Group Centre for Health Economics University of York. Eur J Heart Failure 2000; 2: 123-32.
2. Cleland JG, Gemmell I, Khand A, Boddy A. Is the prognosis of heart failure improving? Eur J Heart Fail 1999; 1: 229-41.
3. Rosolova H, Cech J, Simon J, et al. Short to long term mortality of patients hospitalised with heart failure in the Czech Republic - a report from the EuroHeart Failure Survey. Eur J Heart Fail 2005; 7: 780-3.
4. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur Heart J Fail 2001; 3: 315-22.
5. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-40.
6. Widimsky P, Zelizko M, Jansky P, Tousek F, Holm F. The incidence, treatment strategies and outcomes of acute coronary syndromes in the "reperfusion network" of different hospital types in the Czech Republic: Results of the Czech evaluation of acute coronary syndromes in hospitalized patients (CZECH) registry. Int J Cardiol 2007; 119: 212-9.
7. Cowburn PJ, Cleland JG, Coats AJ, Komajda M. Risk stratification in chronic heart failure. Eur Heart J 1998; 19: 696-710. (Review)
8. Cleland JG, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003; 24: 442-63.
9. Spinar J, Vitovec J, Spac J, Blaha M, Spinarova L, Toman J. Non-invasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. Int J Cardiol 1996; 56: 283-8.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am Stat Assoc 1958; 53: 457-81.
11. O'Connell JB. The economic burden of heart failure. Clin Cardiol 2000; 23: III6-10.
12. Schaufelberger M, Swedberg K, Köster M, Rosén M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J 2004; 25: 300-7.
13. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002; 4: 361-71.
14. Cleland JG, Tendera M, Adamus J, et al. Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999; 1: 211-7.
15. Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005; 352: 1539-49.
16. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
17. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-83.
18. Pitt B: ACE inhibitors for patients with vascular disease without left ventricular dysfunction - may they rest in PEACE? N Engl J Med 2004; 351: 2115-7.
19. Rydén L, Armstrong PW, Cleland JG, et al. Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000; 21: 1967-78.
20. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-36.
21. Fonarow GC; ADHERE Scientific Advisory Committee. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med 2003; 4: S21-30. (Review)
22. Fonarow GS, Adams K, Strausser BP. ADHERE (Acute Decompensated Heart Failure National Registry): Rationale, design and subject population. J Card Fail 2002; 8: S49.
23. Sosin MD, Bhatia GS, Zarifis J, Davis RC, Lip GY. An 8-year follow-up study of acute admissions with heart failure in a multiethnic population. Eur J Heart Fail 2004; 6: 669-72.
24. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
25. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-97.
27. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
28. Braunwald E, Domanski MJ, Fowler SE, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-68.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
30. Rosolova H, Cech J, Simon J, Mayer O, Spinar J, Jandova R. Control of blood pressure in patients with congestive heart failure and diabetes. J Hypertens 2004; 22: 240.
31. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25: 1751-62.
32. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601-10.
33. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practise. European guidelines on cardiovascular disease prevention in clinical pactice: executive summary. Eur Heart J 2007; 28: 2375-414.
34. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-26
35. Anand IS, Tam SW, Rector TS, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007; 49: 32-9.
36. Brophy JM, Dagenais GR, McSherry F, Williford W, Yusuf S. A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. Am J Med 2004; 116: 300-4.
37. Siirilä-Waris K, Lassus J, Melin J, et al; FINN-AKVA Study Group. Characteristics, outcomes, and predictors of 1-year mortality in patients hospitalized for acute heart failure. Eur Heart J 2006; 27: 3011-7.
38. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997; 3: 249-54.
39. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002; 39: 1567-73.
40. Kjekshus J, Apetrei E, Barios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.
41. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total chosterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8: 216-24.
42. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol 2003; 42: 1933-40.
43. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43: 1439-44. (Review)